| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Iain L Lamont | |
| Jessica M Thomson | |||
| P2860 | cites work | A new antibiotic kills pathogens without detectable resistance | Q24091299 |
| Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis | Q24235637 | ||
| Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase | Q24629039 | ||
| Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro | Q24656698 | ||
| Structure and dynamics of thioguanine-modified duplex DNA | Q27639874 | ||
| Lassomycin, a Ribosomally Synthesized Cyclic Peptide, Kills Mycobacterium tuberculosis by Targeting the ATP-Dependent Protease ClpC1P1P2 | Q27682707 | ||
| Fluorinated pyrimidines, a new class of tumour-inhibitory compounds | Q28214124 | ||
| Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD | Q28258977 | ||
| Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2′-deoxyuridine; 5′-iodo-2′-deoxycytidine; 5-iodo-5′-amino-2′,5′-didoxyuridine | Q28325236 | ||
| Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U) | Q28361768 | ||
| Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine | Q28372167 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis | Q33270273 | ||
| Failure of high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable toxicity | Q33333180 | ||
| Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy | Q33357288 | ||
| Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance | Q33749111 | ||
| Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients | Q33860643 | ||
| Discovery research: the scientific challenge of finding new antibiotics | Q33941796 | ||
| Incorporation and excision of 5-fluorouracil from deoxyribonucleic acid in Escherichia coli | Q34116328 | ||
| Nucleoside analogues and nucleobases in cancer treatment. | Q34141323 | ||
| 5-Fluorouracil derivatives: a patent review. | Q34253978 | ||
| The clinical pharmacology of 6-mercaptopurine | Q34265967 | ||
| Testing Nucleoside Analogues as Inhibitors of Bacillus anthracis Spore Germination In Vitro and in Macrophage Cell Culture | Q34309440 | ||
| Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity | Q34338060 | ||
| Gemcitabine-induced pulmonary toxicity: case report and review of the literature | Q34514352 | ||
| A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa Virulence | Q34539031 | ||
| Cellular pharmacology of gemcitabine | Q34542801 | ||
| Toxicity and tolerance mechanisms for azidothymidine, a replication gap-promoting agent, in Escherichia coli | Q34612485 | ||
| Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner | Q34646743 | ||
| Platforms for antibiotic discovery | Q34694926 | ||
| Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer | Q34728470 | ||
| Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs | Q34899246 | ||
| Treatment of pediatric acute lymphoblastic leukemia | Q35196702 | ||
| In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections | Q35326340 | ||
| Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections | Q35336154 | ||
| Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria | Q35601295 | ||
| Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora | Q35648327 | ||
| Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria | Q35912686 | ||
| High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance | Q36410455 | ||
| AN EARLY PHASE IN THE BACTERICIDAL ACTION OF 5-FLUOROURACIL ON E. COLI K(12). OSMOTIC IMBALANCE. | Q36429575 | ||
| THE MECHANISM OF BACTERIAL FRAGILITY PRODUCED BY 5-FLUOROURACIL: THE ACCUMULATION OF CELL WALL PRECURSORS. | Q36432040 | ||
| Bone marrow toxicity associated with 5-fluorocytosine therapy | Q36459546 | ||
| Uracil influences quorum sensing and biofilm formation in Pseudomonas aeruginosa and fluorouracil is an antagonist | Q37273573 | ||
| The clinical consequences of antimicrobial resistance | Q37589107 | ||
| Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis | Q37683527 | ||
| Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes | Q37729532 | ||
| Gemcitabine-induced pulmonary toxicity | Q38044892 | ||
| Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. | Q38110693 | ||
| Multicomponent reactions in nucleoside chemistry. | Q38243795 | ||
| Nucleoside antibiotics: biosynthesis, regulation, and biotechnology. | Q38282006 | ||
| Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? | Q38614305 | ||
| Flucytosine | Q39618637 | ||
| 5-Fluorouracil sensitivity varies among oral micro-organisms | Q39687213 | ||
| Intracellular activity of zidovudine (3'-azido-3'-deoxythymidine, AZT) against Salmonella typhimurium in the macrophage cell line J774-2 | Q39869413 | ||
| Preclinical characteristics of gemcitabine. | Q41040899 | ||
| Idoxuridine and Bacterial Corneal Infection | Q41532425 | ||
| 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines | Q41533544 | ||
| The complex mechanism of antimycobacterial action of 5-fluorouracil | Q41579420 | ||
| Synergistic antimicrobial activities of folic acid antagonists and nucleoside analogs | Q41870463 | ||
| Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections | Q41919457 | ||
| 5-Fluorouracil and mucopeptide biosynthesis by Staphylococcus aureus | Q42272739 | ||
| Antimicrobial activities of trimethoprim/sulfamethoxazole, 5-iodo-2′-deoxyuridine and rifampicin against Staphylococcus aureus | Q42858775 | ||
| Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization | Q42937090 | ||
| Emerging pathogens: is Mycobacterium avium subspecies paratuberculosis zoonotic? | Q43218188 | ||
| Synthesis and in vitro antibacterial activity of novel 5'-O-analog derivatives of zidovudine as potential prodrugs | Q43980402 | ||
| An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. | Q44417439 | ||
| Molecular characterization of thymidine kinase from Ureaplasma urealyticum: nucleoside analogues as potent inhibitors of mycoplasma growth | Q44655562 | ||
| Effect of fluoropyrimidines on the growth of Ureaplasma urealyticum | Q45167762 | ||
| Impact of gemcitabine on the treatment of metastatic pancreatic cancer | Q45195251 | ||
| Isolation of zidovudine resistant Escherichia coli from AIDS patients | Q46909495 | ||
| Thymidine kinase of bacteria: activity of the enzyme in actinomycetes and related organisms | Q50208047 | ||
| Mechanisms of zidovudine resistance in bacteria | Q50463082 | ||
| Zidovudine resistance in clinically significant bacterial isolates from AIDS patients | Q54285695 | ||
| Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. | Q54317760 | ||
| Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. | Q54363293 | ||
| The Mechanism of an Osmotic Instability Induced in E. coli K-12 by 5-Fluorouracil* | Q57077320 | ||
| Azidothymidine Produces Synergistic Activity in Combination with Colistin against Antibiotic-Resistant Enterobacteriaceae. | Q58100712 | ||
| Drug Repurposing for the Treatment of Bacterial and Fungal Infections | Q61808000 | ||
| Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in | Q64107158 | ||
| Synergistic activity of colistin with azidothymidine against colistin-resistant Klebsiella pneumoniae clinical isolates collected from inpatients in Greek hospitals | Q64128390 | ||
| Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine | Q68408993 | ||
| Induction of apoptosis by gemcitabine | Q71542214 | ||
| On the initial stage in peptidoglycan synthesis. Effect of 5-fluorouracil substitution on phospho-N-acetylmuramyl-pentapeptide translocase (uridine 5'-phosphate) | Q72219556 | ||
| The catabolism of uracil in vivo and in vitro | Q73619588 | ||
| Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine | Q78946270 | ||
| Identification of an in vivo inhibitor of Bacillus anthracis spore germination | Q79765323 | ||
| The global distribution and evolution of deoxyribonucleoside kinases in bacteria | Q82366401 | ||
| Zidovudine: A salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections? | Q88180379 | ||
| Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary | Q91340127 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 952 | |
| P577 | publication date | 2019-05-22 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | Nucleoside Analogues as Antibacterial Agents. | |
| P478 | volume | 10 |
Search more.